3500 Lenox Road NE
Suite 1500
Atlanta, GA 30326
United States
844 722 6333
https://www.alzamend.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 4
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Stephan Jackman | CEO & Director | 473.12k | N/A | 1977 |
Mr. Kenneth S. Cragun CPA | Sr. VP of Fin. | N/A | N/A | 1961 |
Mr. David J. Katzoff | Chief Financial Officer | N/A | N/A | 1963 |
Mr. Henry C. W. Nisser Esq. | Exec. VP, Gen. Counsel & Director | N/A | N/A | 1969 |
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Alzamend Neuro, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.